Cme (CME) Cash & Equivalents (2009 - 2026)

Cme (CME) has 18 years of Cash & Equivalents data on file, last reported at $2.4 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $2.4 billion, up 70.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 70.16% YoY), and the FY2025 annual result was $4.4 billion, up 52.71% from the prior year.
• Cash & Equivalents eased to $2.4 billion in Q1 2026 per CME's latest filing, from $4.4 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $4.4 billion in Q4 2025 and troughed at $1.4 billion in Q1 2025.
• A 5-year average of $2.3 billion and a median of $2.1 billion in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents soared 118.46% in 2022, then retreated 23.49% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $2.7 billion in 2022, then grew by 7.05% to $2.9 billion in 2023, then dropped by 0.67% to $2.9 billion in 2024, then soared by 52.71% to $4.4 billion in 2025, then tumbled by 45.86% to $2.4 billion in 2026.
• Business Quant data shows CME's Cash & Equivalents at $2.4 billion in Q1 2026, $4.4 billion in Q4 2025, and $2.4 billion in Q3 2025.